Abstract 422P
Background
Despite previous research highlighting treatment delay inequities in early-stage breast cancer specifically in historically marginalized groups, there is limited research on disparities in Metastatic Breast Cancer (MBC) treatment delays. This study explores treatment delay disparities in MBC treatment initiation aiming to identify contributing factors crucial for improving timely access to care for all.
Methods
Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with MBC in the U.S. between 2011 and 2022. Treatment delay, defined as a binary variable (1 for delays >60 days between diagnosis and first-line treatment), was assessed. Statistical tests (t-tests and chi-squared) were used to analyze patient characteristics (age, race, health insurance, stage at diagnosis, site of metastasis, phenotypes, etc.) among groups with and without treatment delays. Logistic regression was employed to evaluate the association between clinical and non-clinical factors and treatment delays.
Results
Among 20,617 patients with MBC, nearly 28% had treatment delays. Patients with treatment delays were younger, uninsured, historically marginalized patients, and newly diagnosed as compared to patients without treatment delays. Logistic regression revealed higher age was associated with lower odds of treatment delays (2%, p=0.01). Patients without health insurance coverage had higher delay odds (OR: 3.16 p=0.001) as compared with those with commercial health insurance. Historically marginalized patients showed a higher likelihood of delays, ranging from 6% for Black patients to 38% for Hispanic patients (p=0.03) compared to White patients.
Conclusions
Our study highlights concerning disparities in MBC treatment delays. Patients from historically marginalized groups, and those without health insurance coverage are more likely to experience delays in MBC treatment initiation. Identifying and addressing these disparities is essential to ensure equitable healthcare and enhance overall outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
American Cancer Society.
Disclosure
G. Kimmick: Financial Interests, Advisory Board, 5/31/2018: Eisai ; Financial Interests, Advisory Board, 3/22/2018-3/23/2018: Boehringer Ingelheim 2018 ; Financial Interests, Advisory Board, 10/1/2020: Immunomedics; Financial Interests, Advisory Board, 3/23/2021: Biotheranostics; Financial Interests, Advisory Board, 7/12/2023: Novartis; Other, Personal, Advisory Role, 2019: Genomic Health 2019, Agendia; Other, Personal, Speaker’s Bureau, Interview with Niel Love 11/19/2021: Research-to-Practice; Financial Interests, Royalties: UpToDate, Springer; Other, Personal and Institutional, Research Funding: Abbott Laboratories, AbbVie, Abraxis BioScience, Alphavax, AstraZeneca, Bionovo, BiPar Sciences, Bristol Meyers Squibb, Celldex Therapeutics, Celsion, EMD Serono, Exelixis, Genentech, GSK (CARG Trial), Incyte Corporation. All other authors have declared no conflicts of interest.
Resources from the same session
425P - The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries
Presenter: Alicia Annamalay
Session: Poster session 15
426P - Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis
Presenter: Maria Eduarda Souza
Session: Poster session 15
427P - The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients
Presenter: Akshara Singareeka Raghavendra
Session: Poster session 15
428P - Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study
Presenter: Noelia Martinez
Session: Poster session 15
429P - Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
Presenter: Ana Leonor Matos
Session: Poster session 15
430P - A novel survival predicting model for breast cancer brain metastasis based on multimodal data
Presenter: Zisheng Wu
Session: Poster session 15
431P - Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
Presenter: Hope Rugo
Session: Poster session 15
432P - Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Presenter: Naoto Ueno
Session: Poster session 15
433TiP - Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Presenter: Sara Tolaney
Session: Poster session 15
434TiP - ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Presenter: Yanchun Meng
Session: Poster session 15